CL2004000398A1 - Compuestos derivados de pirazolopiridinas, sus sales; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar enfermedades mediadas por quinasas p38, en especial por citocinas, tnf-alfa, il-1, il-6 y/o il-8, tales como enfermedad - Google Patents

Compuestos derivados de pirazolopiridinas, sus sales; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar enfermedades mediadas por quinasas p38, en especial por citocinas, tnf-alfa, il-1, il-6 y/o il-8, tales como enfermedad

Info

Publication number
CL2004000398A1
CL2004000398A1 CL200400398A CL2004000398A CL2004000398A1 CL 2004000398 A1 CL2004000398 A1 CL 2004000398A1 CL 200400398 A CL200400398 A CL 200400398A CL 2004000398 A CL2004000398 A CL 2004000398A CL 2004000398 A1 CL2004000398 A1 CL 2004000398A1
Authority
CL
Chile
Prior art keywords
pirazolopiridinas
citocines
alfa
kinases
tnf
Prior art date
Application number
CL200400398A
Other languages
English (en)
Inventor
Rosales Carmen Virgili Almansa
Original Assignee
Uriach Y Compania S A J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32930978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2004000398(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from ES200300640A external-priority patent/ES2214150B1/es
Priority claimed from ES200300727A external-priority patent/ES2214976B1/es
Application filed by Uriach Y Compania S A J filed Critical Uriach Y Compania S A J
Publication of CL2004000398A1 publication Critical patent/CL2004000398A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CL200400398A 2003-02-27 2004-02-27 Compuestos derivados de pirazolopiridinas, sus sales; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar enfermedades mediadas por quinasas p38, en especial por citocinas, tnf-alfa, il-1, il-6 y/o il-8, tales como enfermedad CL2004000398A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200300640A ES2214150B1 (es) 2003-02-27 2003-02-27 "nuevos derivados de pirazolopiridinas".
ES200300727A ES2214976B1 (es) 2003-03-14 2003-03-14 "nuevos derivados de pirazolopiridinas".
ES200302504 2003-10-27

Publications (1)

Publication Number Publication Date
CL2004000398A1 true CL2004000398A1 (es) 2005-03-18

Family

ID=32930978

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200400398A CL2004000398A1 (es) 2003-02-27 2004-02-27 Compuestos derivados de pirazolopiridinas, sus sales; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar enfermedades mediadas por quinasas p38, en especial por citocinas, tnf-alfa, il-1, il-6 y/o il-8, tales como enfermedad

Country Status (30)

Country Link
US (3) US7468376B2 (es)
EP (1) EP1611131B1 (es)
JP (1) JP4814783B2 (es)
KR (1) KR101312736B1 (es)
AR (1) AR043416A1 (es)
AT (1) ATE481402T1 (es)
AU (1) AU2004215644B2 (es)
BR (1) BRPI0407811A (es)
CA (1) CA2515197C (es)
CL (1) CL2004000398A1 (es)
CY (1) CY1111544T1 (es)
DE (1) DE602004029145D1 (es)
DK (1) DK1611131T3 (es)
EC (2) ECSP056041A (es)
HK (1) HK1085214A1 (es)
HR (1) HRP20050682B1 (es)
IL (1) IL196021A (es)
IS (1) IS2875B (es)
MX (1) MXPA05009069A (es)
NO (1) NO331917B1 (es)
NZ (1) NZ541836A (es)
PE (1) PE20050521A1 (es)
PL (1) PL378296A1 (es)
PT (1) PT1611131E (es)
RS (1) RS51768B (es)
RU (1) RU2359971C2 (es)
SI (1) SI1611131T1 (es)
TW (1) TWI325865B (es)
UA (1) UA81453C2 (es)
WO (1) WO2004076450A1 (es)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004215644B2 (en) * 2003-02-27 2010-09-02 Palau Pharma, S.A. Pyrazolopyridine derivates
ES2241496B1 (es) * 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridina.
AR050188A1 (es) * 2004-08-03 2006-10-04 Uriach Y Compania S A J Compuestos heterociclicos condensados utiles en terapia como inhibidores de quinasas p38 y composiciones farmaceuticas que los contienen
GB0427604D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
PE20061119A1 (es) 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
FR2880891B1 (fr) * 2005-01-19 2007-02-23 Aventis Pharma Sa Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation
CA2611296A1 (en) * 2005-06-27 2007-01-04 Sanofi-Aventis Pyrazolopyridine derivatives as inhibitors of beta-adrenergic receptor kinase 1
CN101243080A (zh) * 2005-06-27 2008-08-13 阿姆布里利亚生物制药公司 作为hiv整合酶抑制剂的吡唑并[3，4-b]吡啶-2-基]-苯甲酸衍生物
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
EP1926734A1 (en) 2005-08-22 2008-06-04 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
EP1919913A2 (en) * 2005-08-25 2008-05-14 F.Hoffmann-La Roche Ag P38 map kinase inhibitors and methods for using the same
BRPI0615270A2 (pt) 2005-08-25 2009-08-04 Hoffmann La Roche pirazol fundido como inibidores de p38 map cinase
JP4584335B2 (ja) * 2005-09-02 2010-11-17 ファイザー・インク ヒドロキシ置換１ｈ−イミダゾピリジンおよび方法
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
AU2006315436A1 (en) 2005-11-15 2007-05-24 Vertex Pharmaceuticals Incorporated Azaindazoles useful as inhibitors of kinases
EP1932845A1 (en) * 2006-12-15 2008-06-18 Bayer Schering Pharma Aktiengesellschaft 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
UY30796A1 (es) * 2006-12-15 2008-07-31 Bayer Schering Pharma Ag 3-h-pirazolopiridinas y sales de éstas, composiciones farmacéuticas que las comprenden, métodos para prepararlas, y sus usos
WO2008104473A2 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Pyrazolopyriidine derivatives and their use as kinase inhibitors
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
US8080546B2 (en) 2007-10-26 2011-12-20 Amgen Inc. Pyrazolo-pyridinone derivatives and methods of use
EP2070929A1 (en) 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
WO2009095752A1 (en) * 2008-01-29 2009-08-06 Glenmark Pharmaceuticals, S.A. Fused pyrazole derivatives as cannabinoid receptor modulators
WO2010093595A1 (en) 2009-02-10 2010-08-19 E. I. Du Pont De Nemours And Company Fungicidal 2-pyridones
WO2010111527A1 (en) * 2009-03-26 2010-09-30 Plexxikon, Inc. Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
EP2464231A4 (en) * 2009-08-10 2013-02-06 Samumed Llc INDAZOLE AS WNT / B-CATENINE SIGNALING PATHWASHER AND THERAPEUTIC APPLICATIONS THEREOF
CA2770116C (en) 2009-08-10 2018-03-13 Epitherix, Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
EP2464647B1 (en) 2009-08-11 2016-09-21 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
FR2951172B1 (fr) * 2009-10-13 2014-09-26 Pf Medicament Derives pyrazolopyridines en tant qu'agent anticancereux
PT3001903T (pt) * 2009-12-21 2017-12-18 Samumed Llc 1h-pirazolo[3,4-b]piridinas e usos terapêuticos destas
EP2593453B1 (en) 2010-07-15 2014-09-17 Bristol-Myers Squibb Company Azaindazole compounds
CN102617548A (zh) * 2011-01-31 2012-08-01 北京赛林泰医药技术有限公司 作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用
AR085392A1 (es) * 2011-02-24 2013-09-25 Cephalon Inc Compuestos de azufre aromaticos sustituidos y metodos para su uso en el tratamiento y prevencion del cancer
IN2014CN02646A (es) 2011-09-14 2015-08-07 Samumed Llc
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
PT2770994T (pt) * 2012-05-04 2019-11-04 Samumed Llc 1h-pirazolo[3,4-b]piridinas e utilizações terapêuticas destas
RU2495039C1 (ru) * 2012-07-31 2013-10-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" МЕТИЛ 3-МЕТИЛ-5-[2-(4-АРИЛАМИНО)-2-ОКСОАЦЕТИЛ]-1,6-ДИФЕНИЛ-1Н-ПИРАЗОЛО[3,4-b]ПИРИДИН-4-КАРБОКСИЛАТЫ И МЕТИЛ 3-МЕТИЛ-5-[2-(4-АРИЛАМИНО)-2-ОКСОАЦЕТИЛ]-6-СТИРИЛ-1-ФЕНИЛ-1Н-ПИРАЗОЛО[3,4-b]ПИРИДИН-4-КАРБОКСИЛАТЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
EP2943198B1 (en) 2013-01-08 2019-07-17 Samumed, LLC 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof
CN104230922B (zh) * 2013-06-19 2016-12-28 中国科学院上海药物研究所 一类五元杂环并吡啶类化合物及其制备方法和用途
AU2014337314B2 (en) * 2013-10-17 2018-12-13 Blueprint Medicines Corporation Compositions useful for treating disorders related to KIT
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040182A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
WO2016040190A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040188A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2017024010A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
US10285982B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10231956B2 (en) 2015-08-03 2019-03-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10166218B2 (en) 2015-08-03 2019-01-01 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10226448B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
US10329309B2 (en) 2015-08-03 2019-06-25 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023972A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023988A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017024021A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023986A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017023984A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10285983B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
US10383861B2 (en) 2015-08-03 2019-08-20 Sammumed, LLC 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017023993A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023989A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
EP3370721A4 (en) 2015-11-06 2019-05-22 Samumed, LLC TREATMENT OF OSTEOARTHRITIS
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
US20170275662A1 (en) * 2016-03-22 2017-09-28 The Quaker Oats Company Method and Apparatus for Controlled Hydrolysis
JP7010851B2 (ja) 2016-06-01 2022-02-10 バイオスプライス セラピューティクス インコーポレイテッド Ｎ－（５－（３－（７－（３－フルオロフェニル）－３Ｈ－イミダゾ［４，５－ｃ］ピリジン－２－イル）－１Ｈ－インダゾール－５－イル）ピリジン－３－イル）－３－メチルブタンアミドを調製するための方法
BR112019008061A2 (pt) 2016-10-21 2019-09-17 Samumed Llc métodos de uso de indazol-3-carboxamidas e seu uso como inibidores da via de sinalização de wnt/b-catenina
US10758523B2 (en) 2016-11-07 2020-09-01 Samumed, Llc Single-dose, ready-to-use injectable formulations
WO2018183712A1 (en) 2017-03-31 2018-10-04 Blueprint Medicines Corporation Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
JOP20190278A1 (ar) 2017-05-31 2019-11-28 Novartis Ag مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN114732910A (zh) 2017-10-05 2022-07-12 弗尔康医疗公司 P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd
GB201721793D0 (en) * 2017-12-22 2018-02-07 Hvivo Services Ltd Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza
CA3136707A1 (en) 2019-04-12 2020-10-15 Blueprint Medicines Corporation Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
PE20212331A1 (es) 2019-04-12 2021-12-14 Blueprint Medicines Corp Derivados de pirrolotriazina para tratar enfermedades mediadas por kit y pdgfra
WO2021067967A1 (en) * 2019-10-04 2021-04-08 University Of Kentucky Research Foundation Preparation of pyrazolo[3,4-b]pyridines as antimalarials

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3403158A (en) 1966-03-11 1968-09-24 Upjohn Co 1h-pyrazolo[3, 4-b]pyridines
US4264603A (en) 1980-03-17 1981-04-28 Sterling Drug Inc. 5-(Pyridinyl)-1H-pyrazolo[3,4-b]pyridine-3-amines, their use as cardiotonics and their preparation
US4361568A (en) 1981-04-28 1982-11-30 Sterling Drug Inc. 5-(Pyridinyl)-1H-pyrazolo[3,4-b]pyridin-3-amines and their cardiotonic use
US4375467A (en) 1981-09-28 1983-03-01 Sterling Drug Inc. 5-(Pyridinyl)-1H-pyrazolo[3,4-b] pyridines and their cardiotonic use
CA2166721C (en) 1993-07-06 1999-07-27 Allen Jacob Duplantier Bicyclic tetrahydro pyrazolopyridines
DE69837282T2 (de) * 1997-12-13 2007-11-08 Bristol-Myers Squibb Co. VERWENDUNG VON PYRAZOLO Ä 3,4-bÜ PYRIDIN ALS CYCLIN-ABHÄNGIGE KINASE HEMMER
US6559152B2 (en) * 1998-10-13 2003-05-06 Dupont Pharmaceuticals Company 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
BR9915011A (pt) 1998-11-03 2001-08-07 Glaxo Group Ltd Compostos, método para a preparação dos mesmos, composição farmacêutica, métodos de tratamento de um indivìduo humano ou animal sofrendo de uma condição que é mediada pela inibição seletiva de cox-2 e sofrendo de um distúrbio inflamatório, e, uso de um composto
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
WO2001030778A1 (en) 1999-10-27 2001-05-03 Novartis Ag Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use
GB9929685D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
ES2236217T3 (es) * 2000-04-25 2005-07-16 Bristol-Myers Squibb Company Uso de 5.tio.,sulfinil- y sulfonilpirazolo 3,4-b)-piridinas como inhibidores de la quinasa dependiente de la ciclina.
EP1287001B1 (en) 2000-06-06 2004-09-29 Pfizer Products Inc. Thiophene derivatives useful as anticancer agents
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
JP2004509891A (ja) 2000-09-22 2004-04-02 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー 抗糖尿病薬としてのピラゾロピリジンおよびピラゾロピリダジン
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
WO2002062795A2 (en) * 2001-02-02 2002-08-15 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds and pharmaceutical use thereof
EP1368355B1 (de) 2001-03-14 2006-06-07 Grünenthal GmbH Substituierte pyrazolo- und thiazolopyrimidine als analgetika
GB0124848D0 (en) 2001-10-16 2001-12-05 Celltech R&D Ltd Chemical compounds
WO2003068773A1 (en) 2002-02-12 2003-08-21 Glaxo Group Limited Pyrazolopyridine derivatives
CA2495216A1 (en) 2002-08-12 2004-02-19 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
UA81790C2 (uk) 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
AU2004215644B2 (en) * 2003-02-27 2010-09-02 Palau Pharma, S.A. Pyrazolopyridine derivates
CA2522430A1 (en) 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
AR044129A1 (es) 2003-05-06 2005-08-24 Altana Pharma Ag Compuestos intermedios de imidazopiridina. proceso de preparacion.
CA2537916A1 (en) 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds

Also Published As

Publication number Publication date
ATE481402T1 (de) 2010-10-15
US8536194B2 (en) 2013-09-17
RS51768B (sr) 2011-12-31
TW200504061A (en) 2005-02-01
JP4814783B2 (ja) 2011-11-16
ECSP12006041A (es) 2012-12-28
DE602004029145D1 (de) 2010-10-28
US20090005377A1 (en) 2009-01-01
JP2006519205A (ja) 2006-08-24
RS20050609A (en) 2007-12-31
NO20053647D0 (no) 2005-07-27
HK1085214A1 (en) 2006-09-29
HRP20050682B1 (hr) 2014-09-12
AU2004215644B2 (en) 2010-09-02
NZ541836A (en) 2008-12-24
WO2004076450A1 (en) 2004-09-10
AU2004215644A1 (en) 2004-09-10
IS2875B (is) 2014-04-15
KR20060002782A (ko) 2006-01-09
US20090286983A1 (en) 2009-11-19
NO331917B1 (no) 2012-04-30
US20060167040A1 (en) 2006-07-27
RU2005130020A (ru) 2006-07-10
EP1611131B1 (en) 2010-09-15
IL196021A (en) 2011-10-31
BRPI0407811A (pt) 2006-02-14
PL378296A1 (pl) 2006-03-20
ECSP056041A (es) 2006-01-27
UA81453C2 (en) 2008-01-10
EP1611131A1 (en) 2006-01-04
US7468376B2 (en) 2008-12-23
DK1611131T3 (da) 2011-01-17
AR043416A1 (es) 2005-07-27
NO20053647L (no) 2005-10-18
KR101312736B1 (ko) 2013-09-27
HRP20050682A2 (en) 2006-05-31
SI1611131T1 (sl) 2011-03-31
PT1611131E (pt) 2010-12-20
IS7939A (is) 2005-07-14
CA2515197C (en) 2011-10-18
IL196021A0 (en) 2009-02-11
CA2515197A1 (en) 2004-09-10
PE20050521A1 (es) 2005-09-11
MXPA05009069A (es) 2005-10-19
RU2359971C2 (ru) 2009-06-27
WO2004076450A8 (en) 2005-09-01
TWI325865B (en) 2010-06-11
CY1111544T1 (el) 2015-08-05

Similar Documents

Publication Publication Date Title
CL2004000398A1 (es) Compuestos derivados de pirazolopiridinas, sus sales; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar enfermedades mediadas por quinasas p38, en especial por citocinas, tnf-alfa, il-1, il-6 y/o il-8, tales como enfermedad
CL2007003832A1 (es) Compuestos derivados de azaespiro; procedimiento de preparacion; composicion farmaceutica; y su uso para prevenir y tratar ansiedad, trastornos depresivos, entre otras enfermedades.
CL2007003635A1 (es) Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer.
CR10868A (es) Derivados de dihidropiridina utiles como inhibidores de la proteina quinasa
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
CL2007001504A1 (es) Compuestos derivados de purina o pirrolopirimidina; y uso para regular, modular o inhibir la actividad de la proteina cinasa en enfermedades tales como cancer, rechazo de transplantes y enfermedades autoinmunes.
CL2007003756A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
EA201270480A1 (ru) Новые соединения
ECSP14004722A (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
UY32302A (es) Carboxamidas heterobicíclicas como inhibidoras de cinasas
DK1948177T3 (da) Anvendelse af flibanserin til behandling af præmenopausale seksuelle lystforstyrrelser
ECSP077235A (es) Benzamidas sustituidas por trifluoro-metilo como inhibidores de quinasa
IL179512A0 (en) Methods of using il-1 antagonists to treat autoinflammatory disease
GT200600316A (es) Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
BRPI0916735B8 (pt) compostos moduladores de tgr5, composições farmacêuticas compreendendo os mesmos e seus usos
BRPI0720270B8 (pt) compostos 4-fenil-6-(2,2,2-triflúor-1-fenil etoxi) pirimidina, composição e forma de dosagem sólida
CL2008001372A1 (es) Compuestos derivados de pirazol sustituidos con heteroarilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar trastornos hiperproliferativos y enfermedades relacionadas con angiogenesis.
CL2007003742A1 (es) Compuestos derivados heterociclicos, inhibidores de protein quinasas activadas por mitogenos; proceso de preparacion; composicion farmaceutica; articulo de manufactura; y uso para el tratamiento de enfermedades tales como trastornos hiperproliferativ
BRPI0816881A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
UY29964A1 (es) Formas de cristal f,g,h,i, y k del mesilato de imatinib
DK1853232T3 (da) Stabil krystallin form af bifeprunox mesylat, doseringsformer deraf og fremgangsmåder for deres anvendelse
DK1841433T3 (da) Præparat til behandling af lidelser i centralnervesystemet
AR054779A1 (es) N-(2,2-dimetilpropil)-6-{3-fluoro-5-[(3-isoxazolilamino)carbonil]-2-metilfenil}-3-piridinacarboxamida